Anti-Mouse/Human IL-5 Antibody (TRFK5)
Based on 1 Customer Validation
Anti-Mouse/Human IL-5 Antibody (TRFK5) is a rat-derived anti-mouse IL-5 IgG1 κ type antibody inhibitor. Anti-Mouse/Human IL-5 Antibody (TRFK5) can significantly decrease eosinophils. Anti-Mouse/Human IL-5 Antibody (TRFK5) shows potent anti- inflammation effect on pulmonary inflammation and asthma.
For research use only. We do not sell to patients.
- Purity: 97.80%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Rat IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human/Mouse
IC50 & Target
IL-5
In Vitro
The antibody framework is stable, specific and adaptable, and has the ability to bind both antigens and endogenous immune receptors. Monoclonal antibodies have several derivatives, including bispecific antibodies, antibody-drug conjugates, and antibody fragments, and have significant effects in fields such as immunology and oncology. When designing inhibitory antibodies, considerations include identification of antigen-specific variable regions, choice of expression system, use of multispecific formats, and antibody derivatives based on fragmentation, oligomerization, or conjugation with other functional moieties[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Anti-Mouse/Human IL-5 Antibody (TRFK5) (1 mg/kg, 1 day before myocardial infarction surgery) abolishes fully the protection of IL-5 for myocardial infarction by depleting eosinophils[2].
Anti-Mouse/Human IL-5 Antibody (1 mg/kg, i.p., a single dose) inhibits pulmonary and blood eosinophilia in Pulmonary inflammation mice models[3].
Anti-Mouse/Human IL-5 Antibody (100 µg, intranasally, a single dose) significantly attenuates pulmonary eosinophilic inflammation and airway hyperresponsiveness[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Chronic asthma micemodels (C57BL/6, female, 6-10 week)[1]
-
Dosage:4 mg/kg
-
Administration:Intraperitoneally injection, every day until killed at day 10
-
Result:Showed a dramatic reduction in the absolute number of eosinophils recovered in BAL fluid.
Significantly increased lymphocytosis in BAL fluid.
Exhibited airway hyperresponsiveness (AHR).
-
Animal Model:Myocardial infarction mice models(C57BL/6, male, 8-10 week)[2]
-
Dosage:1 mg/kg
-
Administration:1 day before myocardial infarction surgery
-
Result:Significant reduced cardiac function and wall thickness, and increased of infarct size.
Muted the inhibitive effects of IL-5 on CD206+ macrophage polarization.
Blocked STAT6 phosphorylation.
-
Animal Model:Pulmonary inflammation mice models (B6D2F1, male, 6-10 weeks)[3]
-
Dosage:1 mg/kg
-
Administration:Intraperitoneally injection
-
Result:Significantly inhibited eosinophil recruitment into BALF.
Inhibited the reduction of eosinophils in the bone marrow.
-
Animal Model:IL-5-induced blood eosinophilia mice models (B6D2F1, male, 6-10 weeks)[3]
-
Dosage:1 mg/kg
-
Administration:Intraperitoneally injection
-
Result:Significantly reduced blood eosinophilia.
Exhibited a dramatic increase in the number of T cells in BALF after 24 weeks.
Increased IL-5 mRNA levels in the lungs.
-
Animal Model:Asthma mice models[4]
-
Dosage:100 µg
-
Administration:Intranasally
-
Result:Decreased total number of cells and the percentage of eosinophils recovered from BALF.
Showed a significant reduction in the magnitude of the lung tissue inflammatory cell infiltration elicited.
Showed lower Rrs responses to methacholine.
Showed higher average values for PD100 and MR.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
in vivo IL-5 neutralization; in vivo eosinophil depletion
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse/Human IL-5 Antibody (TRFK5)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (265 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Mathur M, et al. TRFK-5 reverses established airway eosinophilia but not established hyperresponsiveness in a murine model of chronic asthma. Am J Respir Crit Care Med. 1999 Feb;159(2):580-7. [Content Brief]
[2]. Xu JY, et al. Interleukin-5-induced eosinophil population improves cardiac function after myocardial infarction. Cardiovasc Res. 2022 Jul 20;118(9):2165-2178. [Content Brief]
[3]. Garlisi CG, et al. Effects of chronic anti-interleukin-5 monoclonal antibody treatment in a murine model of pulmonary inflammation. Am J Respir Cell Mol Biol. 1999 Feb;20(2):248-55. [Content Brief]
[4]. Shardonofsky FR, et al. Therapeutic efficacy of an anti-IL-5 monoclonal antibody delivered into the respiratory tract in a murine model of asthma. J Allergy Clin Immunol. 1999 Jul;104(1):215-21. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-Mouse/Human IL-5 Antibody (TRFK5) Related Classifications
HY-P990213 Related Classifications
Powered by Bioz